Journal
BRITISH JOURNAL OF HAEMATOLOGY
Volume 160, Issue 4, Pages 503-509Publisher
WILEY-BLACKWELL
DOI: 10.1111/bjh.12181
Keywords
Acute Myeloid Leukaemia; WT1; allogeneic stem cell transplantation
Categories
Funding
- Associazione Italiana Ricerca contro il Cancro (A.I.R.C.) Milano
- Fondi FInalizzati
- Ministero Salute, Italia
- FARITMO Genova
- CARIGE Genova, Italy
Ask authors/readers for more resources
We assessed WT1 expression (expressed as messenger copies/104 ABL1) from marrow cells of 122 patients with acute myeloid leukaemia (AML), before and after an unmanipulated allogeneic haemopoietic stem cell transplant (HSCT). The median age was 44 years (1569), 59% were in first remission, 74% received a myeloablative conditioning regimen and the median follow up was 865 d (342833). Relapse was higher in 67 patients with WT1 expression, at any time post-HSCT, exceeding 100 copies (54%), as compared to 16%, for 55 patients with post-HSCT WT1 expression <100 copies (P < 0.0001). Similarly, actuarial 5-year survival (OS) was 40% vs. 63%, respectively (P = 0.03). In multivariate Cox analysis, WT1 expression post-HSCT was the strongest predictor of relapse (Hazard Ratio [HR] 4.5, P = 0.0001), independent of disease phase (HR 2.3, P = 0.002). Donor lymphocyte infusions (DLI) were given to 17 patients because of increasing WT1 levels: their OS was 44%, vs. 14% for 21 patients with increasing WT1 expression who did not receive DLI (P = 0.004). In conclusion, WT1 expression post-HSCT is a strong predictor of leukaemia relapse and survival in AML; WT1 may be used as a marker for early interventional therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available